Natera’s Rabinowitz sells $87k in shares to cover tax obligations

Daniel Rabinowitz, Secretary and Chief Legal Officer at Natera, Inc. (NASDAQ:NTRA), sold 464 shares of common stock on October 21, 2025, at a price of $187.95, totaling $87,208. The transaction comes as Natera’s stock trades near its 52-week high, having delivered an impressive 53% return over the past year. According to InvestingPro analysis, the company currently appears overvalued at its market capitalization of $25.94 billion.

According to a Form 4 filing with the Securities and Exchange Commission, the sale was to satisfy tax withholding and remittance obligations related to the vesting of Restricted Stock Units (RSUs). On October 20, Rabinowitz also exercised 856 Restricted Stock Units, each representing a contingent right to receive one share of Natera’s common stock. The price per share for the exercised RSUs was $0.

Following these transactions, Rabinowitz directly owns 203,692 shares of Natera, Inc.

In other recent news, Natera has made several notable announcements and developments. The company has enrolled over 1,600 patients in its EXPAND trial, which is evaluating the Fetal Focus single gene noninvasive prenatal test for inherited conditions. This study aims to confirm test results through diagnostic testing and includes a diverse, multi-ethnic population. Natera also reported that its Signatera test significantly outperformed standard tumor markers in a study of testicular cancer patients, with findings published in the Journal of Clinical Oncology - Precision Oncology. Additionally, the Signatera test showed strong results for monitoring recurrence and treatment response in early-stage uterine cancer patients, as published in the same journal.

In the realm of analyst ratings, Wells Fargo resumed coverage of Natera with an Equal Weight rating and a price target of $175, highlighting the company’s strong position in cell-free DNA testing technology. Meanwhile, Canaccord Genuity maintained its Buy rating and a $200 price target for Natera, emphasizing its leadership in molecular residual disease testing. These developments come as Natera prepares to present 14 abstracts at the upcoming European Society for Medical Oncology Congress.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.